TRiCares | Biotech & Life Sciences | F4

F4/TRiCares

Company Overview Backed By Recent Activity Similar Companies Startup DNA

TRiCares

TRiCares is a medical device company focused on developing a catheter-based tricuspid valve replacement system for patients suffering from severe tricuspid regurgitation (TR), aiming to provide a minimally invasive treatment option without the need for open-heart surgery

tricares.com

Biotech & Life Sciences

Sector

Seed

Stage

Medical device manufacturing

Model

01Company Overview

02Backed By2 investors

4C415 Capital→APAndera Partners→

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

Recent Activity

FROM 415 Capital

Portfolio company TRiCares announced initiation of its TRICURE US IDE pivotal study for the Topaz tricuspid valve replacement system.

MILESTONE·415capital.com

JUL 9, 2026

FROM 415 Capital

Portfolio company TRiCares received FDA approval for its TRICURE US IDE pivotal trial.

MILESTONE·415capital.com

APR 7, 2026

FROM 415 Capital

Portfolio company TRiCares entered into a €20 million loan agreement with the European Investment Bank.

MILESTONE·415capital.com

JAN 20, 2026

FROM 415 Capital

Portfolio company TRiCares completed its first TC-L 55mm Topaz implant in the ongoing TRICURE EU pivotal study.

MILESTONE·415capital.com

NOV 6, 2025

04Similar Companies

C

CroíValve

Biotech & Life Sciences

→

C

CardiAQ

Biotech & Life Sciences

→

CB

Cardiac Booster

Biotech & Life Sciences

→

JT

JenaValve Technology

Biotech & Life Sciences

→

LI

Laplace Interventional

Healthcare & Digital Health

→

05Startup DNA

signals

Sectors
Business Model
Technology

Quick Reference

Sector

Biotech & Life Sciences · Healthcare & Digital Health

Website

tricares.com

Visit tricares.com ↗